Drug intelligence / Profile preview

Lipovenos

Development stage: Unknown
Lead developer: Fresenius Kabi
Administration: Intravenous

Overview

Lipovenos is a sterile, pyrogen-free lipid emulsion primarily used for parenteral nutrition, providing energy and essential fatty acids to patients unable to maintain normal oral intake. Its typical composition includes soybean oil, glycerol, and egg phospholipids, with some formulations also containing medium-chain triglycerides. It functions by delivering lipids that are metabolized similarly to physiological chylomicrons, releasing fatty acids and glycerol for energy production and cellular structure. In a research context, a '20% lipid/heparin' formulation of Lipovenos has been used to induce hyperlipidaemia to study its effects on the hypothalamic-pituitary-adrenal (HPA) axis.

Brand names: LipovenosLipovenos 20%Lipovenos MCTLipovenos MCT/LCT
Other names: LipovenousLipovenoes MCT 20%

Targets

LPL (Lipoprotein lipase)

Beyond the preview

Go deeper on Lipovenos.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipovenos.

Explore the full profile